Johan Hansson

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Omid Hamid, Henrik Schmidt, Aviram Nissan et al. · Journal of Translational Medicine · 2011 · 531 citations · Full text

Medicine, Immunology, Oncology +17

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

Isabel Poschke, Dimitrios Mougiakakos, Johan Hansson et al. · Cancer Research · 2010 · 377 citations · Full text

Medicine, Immunology, Oncology +17

ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma

Daníel F. Guðbjartsson, Patrick Sulem, Simon Stacey et al. · Nature Genetics · 2008 · 355 citations

Medicine, Dermatology, Oncology +16

Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.

Masanori Matsuda, Flavio Salazar, Max Petersson et al. · The Journal of Experimental Medicine · 1994 · 310 citations · Full text

Life Sciences, Immunology, Oncology +17